Cargando…
New Trends in the Molecular and Biological Basis for Clinical Oncology
Newly developed molecular target anticancer drugs have shown remarkable efficacy even in the treatment of intractable cancers such as hepatoma and renal cell carcinoma. As cancer research is becoming a multidisciplinary endeavor, close cooperation across the basic, translational, and clinical resear...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Tokyo :
Springer Japan : Imprint: Springer,
2009.
|
| Edición: | 1st ed. 2009. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-4-431-88663-1 | ||
| 003 | DE-He213 | ||
| 005 | 20220118165809.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2009 ja | s |||| 0|eng d | ||
| 020 | |a 9784431886631 |9 978-4-431-88663-1 | ||
| 024 | 7 | |a 10.1007/978-4-431-88663-1 |2 doi | |
| 050 | 4 | |a RC254-282 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a New Trends in the Molecular and Biological Basis for Clinical Oncology |h [electronic resource] / |c edited by Tetsuhiko Tachikawa, Nose Kiyoshi, Tohru Ohmori, Mitsuru Adachi. |
| 250 | |a 1st ed. 2009. | ||
| 264 | 1 | |a Tokyo : |b Springer Japan : |b Imprint: Springer, |c 2009. | |
| 300 | |a XVIII, 192 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a RTK-Related Signaling -- HER2 Overexpression Attenuates the Antiproliferative Effect of Aromatase Inhibitor in MCF-7 Breast Cancer Cells Stably Expressing Aromatase -- Biomarker Research for Development of Molecular Target Agents -- Epidermal Growth Factor (EGF) Receptor Kinase Activity is Required for Tumor Necrosis Factor (TNF)-? Mediated Intestinal Epithelial Survival -- A Molecular Mechanism of Diminished Binding Activity between 15 bp Deletion Mutant EGFR and c-Cbl Ubiquitin Ligase -- Inflammation, Angiogenesis, and Tumor Progression -- TGF?-Mediated Epithelial Mesenchymal Transition and Metastasis in Skin and Head-and-Neck Cancer -- TGF-? and Tumor Progression Mediated by Reactive Oxygen Species -- Role of MT1-MMP in Tumor-Stromal Interaction -- Role of Proinflammatory Prostaglandin E2 in Bladder Tumor Progression -- Biomarkers for Clinical Oncology -- Molecular Biomarker for Lung Cancer -- Screening of Biomarker for Oral Squamous Cell Carcinoma Correlating with Clinicopathological Findings Using by Laser Microdissection and cDNA Microarray -- Biomarkers for Clinical Oncology -- Genome-Wide cDNA Microarray Screening of Gene Expression Profiles Correlated with Resistance to Anti-Cancer Drug Treatment and Radiation in Oral Squamous Cell Carcinoma -- Poster Session -- Drug Accumulation and Efflux Do not Contribute to Acquired Gefitinib Resistance -- Difference of EGFR-Binding Proteins between Wild Type and Mutant EGFR -- Competitive Nuclear Export of Cyclin D1 and Hic-5 Regulates Anchorage-Dependence of Cell Growth and Survival -- Induction of Matrix Metalloprotease Gene Expression in an Endothelial Cell Line by Direct Interaction with Malignant Cells -- Expression of Rad21 Cleaved Products in Oral Epithelium -- Telomerase-Specific Replication-Selective Virotherapy for Oral Squamous Cell Carcinoma Cell Lines -- Hypoxia Induces Resistance to 5-Fluorouracil in Oral Cancer Cells Via G1 Phase Cell Cycle Arrest. | |
| 520 | |a Newly developed molecular target anticancer drugs have shown remarkable efficacy even in the treatment of intractable cancers such as hepatoma and renal cell carcinoma. As cancer research is becoming a multidisciplinary endeavor, close cooperation across the basic, translational, and clinical research fields holds the promise of further advances in cancer therapeutics. This book sets forth new strategies for development: cancer therapy targeting receptor tyrosine kinases with clinical utilization of new signaling regulations; interaction between cancer progression and extracellular environments such as inflammatory cytokines and the extracellular matrix; and investigation of biomarkers for personalized cancer therapy, with microarray analysis and pharmacogenomics technology. These and other findings from the latest investigations into cancer cell biology and therapeutics make this book an invaluable source for investigators in both the clinical and basic cancer research fields. | ||
| 650 | 0 | |a Oncology. | |
| 650 | 1 | 4 | |a Oncology. |
| 700 | 1 | |a Tachikawa, Tetsuhiko. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Kiyoshi, Nose. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Ohmori, Tohru. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Adachi, Mitsuru. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9784431998648 |
| 776 | 0 | 8 | |i Printed edition: |z 9784431889458 |
| 776 | 0 | 8 | |i Printed edition: |z 9784431886624 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-4-431-88663-1 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||